Amryt Pharma PLC Change of Registered Address (7962T)
July 06 2018 - 1:00AM
UK Regulatory
TIDMAMYT
RNS Number : 7962T
Amryt Pharma PLC
06 July 2018
6 July 2018
AIM: AMYT
ESM: AYP
Amryt Pharma plc
("Amryt" or the "Company")
Change of Registered Address
Amryt, a biopharmaceutical company focused on rare and orphan
diseases, announces that it has changed its registered office
address with immediate effect to:
Dept 920A
196 High Road
Wood Green
London N22 8HH
United Kingdom
Enquiries:
Amryt Pharma plc +353 (1) 518 0200
Joe Wiley, CEO
Rory Nealon, CFO/COO
Stifel +44 (0) 20 7710 7600
Joint Broker
Jonathan Senior, Ben Maddison
Davy +353 (1) 679 6363
ESM Adviser and Joint Broker
John Frain, Anthony Farrell
Shore Capital +44 (0) 20 7408 4090
NOMAD and Joint Broker
Edward Mansfield, Mark Percy, Daniel
Bush
Consilium Strategic Communications +44 (0) 20 3709 5700
Amber Fennell, Matthew Neal, Nicholas
Brown
About Amryt
Amryt is a biopharmaceutical company focused on developing and
delivering innovative new treatments to help improve the lives of
patients with rare or orphan diseases.
Lojuxta is an approved treatment for adult patients with the
rare cholesterol disorder - Homozygous Familial
Hypercholesterolaemia ("HoFH"). This disorder impairs the body's
ability to remove low density lipoprotein ("LDL") cholesterol
("bad" cholesterol) from the blood, typically leading to abnormally
high blood LDL cholesterol levels in the body and subsequent
aggressive and premature narrowing and blocking of blood vessels.
Lojuxta is indicated as an adjunct to a low-fat diet and other
lipid-lowering medicinal products with or without LDL apheresis in
adult patients with HoFH.
Amryt holds an exclusive licence to sell Lojuxta (lomitapide)
across the European Economic Area, Middle East and North Africa,
Switzerland, Turkey, Israel, Russia, the Commonwealth of
Independent States and the non-EU Balkan states.
Amryt's lead drug candidate, AP101, is a potential treatment for
Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin
disorder affecting young children for which there is currently no
treatment. It is currently in Phase 3 clinical trials. The European
and US market opportunity for EB is estimated to be in excess of
EUR1.3 billion.
Amryt's earlier stage product AP102 is focused on developing
novel, next generation somatostatin analogue ("SSA") peptide
medicines for patients with rare neuroendocrine diseases, where
there is a high unmet medical need, including acromegaly and
Cushing's disease.
In March 2018, Amryt in-licensed a pre-clinical gene-therapy
platform technology, AP103, which offers a potential treatment for
patients with Recessive Dystrophic Epidermolysis Bullosa, a subset
of EB, and is also potentially relevant to other genetic
disorders.
For more information on Amryt, please visit amrytpharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
CROLIFLIDRIRIIT
(END) Dow Jones Newswires
July 06, 2018 02:00 ET (06:00 GMT)
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Apr 2024 to May 2024
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From May 2023 to May 2024